Skip to search formSkip to main contentSkip to account menu

BAL27862

National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

BenzimidazolesOxadiazoles

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
A Phase 1 study of BAL101553, a novel tumor checkpoint controller targeting microtubules, administered as 48-h infusion in adult patients with advanced solid tumors
Purpose BAL101553, the prodrug of the microtubule-destabilizer BAL27862, previously showed signs of antitumor activity when… 
2017
2017
The novel microtubule targeting agent BAL101553 in combination with radiotherapy in treatment-refractory tumor models.
2017
2017
Abstract LB-151: The novel tubulin-binding, tumor checkpoint controller BAL101553 has differential effects on tumor vascularization with IV and oral dosing and provides superior anti-tumor activity…
Background: BAL101553 is a highly soluble prodrug of BAL27862, a novel, small molecule, microtubule-depolymerizer inducing tumor… 
2016
2016
Phase 1/2a trial of intravenous BAL101553, a novel tumor checkpoint controller (TCC), in advanced solid tumors.
2525Background: BAL101553 (prodrug of BAL27862) is a small molecule TCC that binds microtubules and promotes tumor cell death… 
2015
2015
Initial testing (stage 1) of BAL101553, a novel tubulin binding agent, by the pediatric preclinical testing program
BAL101553 is a highly water soluble prodrug of BAL27862 that arrests tumor cell proliferation and induces cell death in cancer… 
2014
2014
Abstract 831: BAL101553 (prodrug of BAL27862): A unique microtubule destabilizer active against drug refractory breast cancers alone and in combination with trastuzumab
Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA Background: BAL101553 is a highly soluble prodrug of… 
2010
2010
Abstract 4412:In vitroactivity of the novel tubulin active agent BAL27862 inMDR1(+) andMDR1(−) human breast and ovarian cancer variants selected for resistance to taxanes
BAL27862 is a synthetic small molecule that induces apoptosis due to the inhibition of tubulin polymerization via a potentially… 
2010
2010
Abstract 1977: BAL27862: A unique microtubule-targeted drug that suppresses microtubule dynamics, severs microtubules, and overcomes Bcl-2- and tubulin subtype-related drug resistance
Microtubule-targeted drugs (MTDs) are widely used to treat human malignancies such as ovarian and breast cancers. However, a… 
2010
2010
Abstract 4419: BAL101553: A highly soluble prodrug of the potent microtubule destabilizer BAL27862
Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DC Background: [BAL27862][1] is a synthetic small… 
2009
2009
BAL27862: A Unique Microtubule Destabilizer Active Against Chemorefractory Breast Cancers.
Background: BAL27862, a novel, synthetic, small molecule, is a potent inhibitor of tubulin polymerization that induces cancer… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)